Chronic Constriction Injury

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Peripheral nerve injury, due to trauma, disease or various sources of toxicity is a cause of chronic pain. This pathology can be readily modeled in rodents with a number of neuropathic pain models that Melior has developed.

The chronic constriction injury (CCI) model is induced by ligation to the sciatic nerve. Melior has experience in developing several versions, including partial and complete sciatic nerve ligation models in rats. Signs of neuropathy typically become apparent within a week after surgery.

The CCI model induces a neuropathic pain response that can be detected by von Frey mechanical thresholds and Hargreaves thermal sensitivity and can be attenuated by administering drugs such as gabapentin, a first-line analgesic for neuropathic pain.

Two weeks after CCI surgery in rats, von Frey mechanical thresholds were significantly reduced in vehicle-treated ipsilateral region of the hind paw compared to contralateral thresholds (Control). After treatment with Gabapentin, ipsilateral hind paw thresholds return to baseline and are significantly increased compared to vehicle-treated ipsilateral thresholds.

In a Hargreaves study of thermal sensitivity, ipsilateral latencies were significantly reduced compared to contralateral latencies in response to heat. Data are mean ± SEM; ***p<0.001 compared to baseline, +++p<0.001 compared to vehicle. (n=6-10).

Ideal group sizes are>10 animals.

Interested in running a Chronic Constriction Injury study?

If you are interested in learning more about the CCI model, please contact us to start the conversation today!

Discuss your project with us

We chose Melior Discovery because they were responsive and cost effective. We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail. Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.
Sridharan Rajamani, Ph.D., Senior Research Scientist
Gilead Sciences
I have been working with Melior on a number of projects over the course of a few years now. They have been a great partner throughout this time. The scientists whom I have worked with have been great problem-solvers and were customer focused
Jay Lichter
Avalon Ventures
[We] have been impressed with [Melior’s] ability to rapidly and effectively evaluate compounds in animal models…as we strive to identify compounds to ameliorate the devastating symptoms of Rett,
Monica Coenraads, Executive Director
Rett Syndrome Research Trust
Melior is more than just a service company. Their experienced staff guided us in our drug development efforts. We consider Melior an extension of our own research team.
Josh Schultz
Carolus Therapeutics
Addex Therapeutics has been collaborating with Melior Discovery for more than a year. The studies performed at Melior are always carefully planned and skilfully executed while the progress of the project is well-tracked and communicated to the customer. On several occasions, when testing our compounds in a new in vivo assay, we relied on Melior's scientists in their guidance and advice. We have been particularly pleased with a series of experiments involving assessment of compounds' profiles in the rat sleep/wake EEG. This approach, that has a translational relevance, offered a sensitive measure of a compound's efficacy and side-effects
Mikhail Kalinichev, Ph.D., Associate Research Director
Addex Therapeutics
Having worked with Melior quite extensively over the past several years, we find the team to be highly knowledgeable, responsive and adaptable to our needs. The overall process has been highly efficient and we are impressed by the quality of their reports
Christopher Prior, Ph.D., CEO,
PhaseBio Pharmaceuticals Inc.
…to evaluate our lead compound in an EEG-based sleep wake model. Melior’s very experienced team provided valuable insights and recommendations on study design, analysis and interpretation of the data. As a virtual company, Prexa relied on Melior to become an extension of our knowledge team and they met all our expectations
Pat Baskin and Ev Graham
Prexa Pharmaceuticals
State of-the-art Preclinical Pharmacology
Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry